Tag: Novartis

More than 25 brand-name and generic medications are currently approved for managing multiple sclerosis, with a diverse field of pharmaceutical companies dedicated to developing and manufacturing these vital treatments. This complex landscape is dominated by several major players who make MS drugs, alongside a growing number of smaller biotech firms.

The brand-name medication Starlix 60 mg has been discontinued, making the discussion of its retail price largely theoretical. However, the cost of its generic equivalent, nateglinide 60 mg, can range significantly depending on the pharmacy, insurance, and whether discount coupons are used. This article explores the current cost landscape and strategies for managing the expense of this important diabetes medication.

In 2023, eye health company Bausch + Lomb acquired Xiidra from Novartis in a deal worth up to $2.5 billion. For patients wondering, “Is Xiidra being discontinued?”, this change in ownership confirms the medication's continued availability and future in the dry eye treatment market.

Since its FDA approval in 2018, Aimovig (erenumab-aooe) has been a key player in migraine prevention [1.2.5]. Despite rumors, if you're asking 'Why was Aimovig discontinued?', the simple answer is: it hasn't been. The confusion stems from a significant change in its commercial partnership.

In clinical trials, many people taking Cosentyx for plaque psoriasis have shown significant improvement. The generic name for Cosentyx is **secukinumab**, and it is important to understand what this means for patients with autoimmune conditions.

As of October 2025, a recall for the prescription medication Xiidra has not been issued. However, confusion may stem from a specific recall of *over-the-counter* (OTC) eye drops and past manufacturing issues, leading many to ask, 'Has Xiidra been recalled?'.

The medication canakinumab, marketed under the brand name Ilaris®, was first approved by the U.S. Food and Drug Administration (FDA) in June 2009. So, who makes canakinumab? The Swiss multinational healthcare company Novartis is the developer and manufacturer of this important biopharmaceutical.

According to official drug regulatory information, the brand-name version of terbinafine, Lamisil, was officially discontinued by its manufacturer, Novartis, several years ago. Despite this, generic terbinafine remains widely available as a first-line treatment for various fungal infections.

A 28-day course of Vijoice (alpelisib) had a wholesale cost of $32,500 in 2022, highlighting the significant financial burden associated with this targeted therapy. This article explores how much alpelisib costs in the US under its different brand names, the factors affecting price, and available financial support.

In June 2022, Novartis Pharmaceuticals initiated a voluntary recall of dozens of lots of the prescription dry eye medication Xiidra (lifitegrast ophthalmic solution) after it was discovered they failed to meet specifications for impurities/degradation. The U.S. Food and Drug Administration (FDA) designated this action as a Class III recall, indicating that use of the affected product was not likely to cause harm.